What drove Moderna's vaccine success? 5 key steps the drugmaker took

When Moderna was founded in 2010, leaders in the pharmaceutical industry guffawed at the idea that mRNA could be useful in medicine. This year, the drugmaker, which only makes products based on mRNA technology, is poised to deliver 1 billion doses of its COVID-19 vaccine and gain $19 billion in revenue, Bloomberg reported July 14.